Synvect is a San Diego-based biotech company founded by scientists from UC San Diego that develops CRISPR-based mosquito suppression technology. Its core product uses CRISPR to create sterile male mosquitoes that mate with wild females to prevent reproduction, a method designed to remain contained and avoid gene drives. The company has received U.S. EPA approval for its first product, SEPARATOR, and is launching pilot programs with government and mosquito control agencies in Florida, Texas, California, and other high-risk regions. Synvect’s approach is positioned as an eco-friendly alternative to chemical pesticides and seeks large-scale deployment to combat rising mosquito-borne diseases. The company is built on 15 years of research and has previously received $20M in prior funding. The recent financing will accelerate development, regulatory engagement, and commercial roll-out in collaboration with government agencies, researchers, and communities.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Mar 2025